This bill amends the Animal Health Protection Act to reauthorize and reshape federal support for animal disease prevention, surveillance, and rapid response. It changes how much and how long USDA must make funds available for the programs in section 10409A, adds explicit appropriations authority for the national laboratory network, and extends several program authorization dates.
The measure matters because it substitutes a substantially larger, front-loaded funding posture for the status quo and routes those resources through the Commodity Credit Corporation (CCC) while also creating multi-year appropriations for laboratory capacity and countermeasures. That combination affects how USDA, state animal health agencies, diagnostic labs, and vaccine/biological suppliers plan operations and budgets and raises questions about sustainability, oversight, and program delivery.
At a Glance
What It Does
The bill requires the Secretary of Agriculture to make CCC funds available to carry out section 10409A on a reauthorized schedule: annual mandatory funding for short and multi‑year blocks, a permanent lower baseline beginning FY2031, and set‑asides within the larger amounts for three subsections of the statutory program. It also authorizes additional appropriations for the National Animal Health Laboratory Network and extends existing program authorization dates to 2030.
Who It Affects
Primary executors include USDA (especially APHIS), state and territorial animal health agencies that receive federal grants or cooperative agreements, the National Animal Health Laboratory Network and affiliated diagnostic labs, and entities involved in the national vaccine/countermeasures bank. Livestock and poultry producers are indirect beneficiaries and stakeholders in surveillance and response activities.
Why It Matters
This bill moves preparedness from modest, year‑to‑year funding into a phase of concentrated federal investment followed by a much-reduced baseline, changing incentives for long‑term capacity building. Using CCC funds shifts financing mechanics away from regular appropriations processes and increases guaranteed outlays over the near term, which affects program planning, contractors, and oversight priorities.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The Foreign Animal Disease Prevention, Surveillance, and Rapid Response Act of 2025 revises the funding architecture for the federal animal disease programs codified at 7 U.S.C. 8308a (section 10409A of the Animal Health Protection Act). It instructs the Secretary of Agriculture to draw on Commodity Credit Corporation resources to provide mandatory funding for these programs across three phases: an initial authorization window, a substantially larger multi‑year funding block, and a reduced ongoing baseline in later years.
The statute specifies minimum dollar allocations to categories within the statute so that certain program areas receive dedicated shares of the larger multi‑year block.
Alongside mandatory CCC disbursements, the bill creates explicit appropriations authority for the National Animal Health Laboratory Network, increasing the authorized annual appropriations in later years compared with earlier ones. The measure also pushes back statutory sunset or authorization dates in related paragraphs of section 10409A so that several program elements remain active through 2030.Practically, the Secretary executes these changes by making CCC funds available each fiscal year in the prescribed amounts and by obligating appropriated funds for laboratory activities.
That process means USDA controls the release and use of money for grants, cooperative agreements, the vaccine/countermeasure bank, and laboratory investments. States and labs will receive funds through existing channels (grants, cooperative agreements, reimbursements), but the bill leaves implementation details—eligibility, reporting, and performance metrics—to the program guidance and agency rulemaking or administrative practice.The overall structure produces a front‑loaded surge of federal resources intended to expand preparedness and response capabilities rapidly, followed by a much smaller steady‑state funding level.
That profile will shape decisions by states, labs, and private suppliers about hiring, capital investment, and long‑term contracts, because the bill guarantees near‑term funding but provides less certainty about sustained investment beyond the new baseline.
The Five Things You Need to Know
The bill requires the Secretary to use Commodity Credit Corporation funds to provide mandatory program funding in three phases rather than only annual appropriations.
For the multi‑year block starting in FY2026, the statute mandates a large annual allotment with specific minimum set‑asides to three subparts of section 10409A (i.e.
separate program categories receive guaranteed shares).
It authorizes additional annual appropriations for the National Animal Health Laboratory Network, increasing the authorized level for later fiscal years compared with earlier ones.
The bill extends existing authorization dates in two provisions of section 10409A so related preparedness and vaccine/countermeasure authorities remain in force through 2030.
Implementation and disbursement authority rests with the Secretary of Agriculture, who will obligate CCC resources and appropriations via USDA program mechanisms (grants, cooperative agreements, and direct obligations).
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Gives the act its public name: the Foreign Animal Disease Prevention, Surveillance, and Rapid Response Act of 2025. This is a drafting formality but signals the bill’s focus on prevention, surveillance, and rapid federal response to foreign animal diseases.
Mandatory funding schedule and set‑asides
This subsection replaces the prior mandatory funding language and prescribes a multi‑phase funding schedule funded from the CCC. It creates an initial authorization period, then a substantially larger multi‑year funding block with explicit minimum amounts allocated to three program categories within section 10409A, and finally a lower recurring baseline for later fiscal years. For practitioners, the practical effect is a guaranteed flow of CCC resources that the Secretary must make available each fiscal year in the specified amounts and proportions, giving USDA discretion over the timing and mechanism of disbursement under existing program authorities.
Authorized appropriations for the National Animal Health Laboratory Network
This change creates a statutory authorization for annual appropriations designated to the National Animal Health Laboratory Network and increases the authorized level in later years. The provision separates appropriated dollars for laboratory capacity from CCC mandatory funding for the broader programs, signaling a congressional intent to fund diagnostics capacity via the regular appropriations process in addition to mandatory program funds.
Extension of program authorization dates
The bill extends the expiration/authorization date in a key subparagraph of section 10409A from an earlier date to 2030. That extension keeps certain preparedness and response authorities active for a longer window, allowing USDA to obligate funds and continue program activities under those statutory authorities through 2030 without seeking a separate reauthorization.
Availability and purpose language updated
This minor textual amendment updates the statute’s cross‑reference to the year through which funds are available and for which program purposes, aligning the availability language with the extended authorization dates elsewhere in the bill. For administrators, this clarifies statutory consistency between the program’s funding availability and the newly extended authorization period.
This bill is one of many.
Codify tracks hundreds of bills on Agriculture across all five countries.
Explore Agriculture in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- USDA / APHIS — Gains larger guaranteed near‑term resources to expand surveillance, diagnostics, and response capacity and more flexibility to plan multi‑year initiatives under section 10409A.
- State and territorial animal health agencies — Stand to receive increased grant and cooperative agreement opportunities for preparedness and surveillance projects, and may secure funds for state lab upgrades and response planning.
- National and regional veterinary diagnostic laboratories — Benefit from separate authorized appropriations for the laboratory network and likely increased capital and operational investments tied to expanded surveillance and testing demands.
- Livestock, poultry, and aquaculture producers — Indirect beneficiaries through stronger detection and faster federal responses that can limit outbreak size, movement restrictions, and economic losses if the programs reduce disease incidence.
Who Bears the Cost
- Commodity Credit Corporation (CCC) funding pool — The bill directs CCC resources to animal health programs, which can crowd out other CCC uses or reduce the CCC’s flexibility for unrelated farm programs.
- U.S. taxpayers / federal budget — Although the CCC is a revolving entity, increased mandatory disbursements and new appropriations increase federal financial commitments over the covered years.
- USDA operational units — Administering a large surge of funds and new programmatic activity will create administrative and oversight burdens that may require internal reorganization or additional staffing, which the bill does not separately fund.
- Diagnostic labs and recipients — With more funding comes more reporting, compliance, and performance obligations; some laboratories or subgrantees may face short‑term capacity strain if funds require rapid scaling of operations.
Key Issues
The Core Tension
The central dilemma is between speed and sustainability: the bill guarantees large, rapid federal investment to dramatically improve preparedness now (via CCC mandatory funding and new appropriations), but it does so in a way that reduces long‑term funding certainty and shifts financing out of the regular appropriations process—improving near‑term capacity while raising risks for long‑term sustainment, oversight, and program accountability.
The bill delivers a very specific funding profile but leaves important program design choices to USDA. It prescribes minimum allocations among statutory subsections without detailing eligible activities, matching requirements, or performance metrics, so much of the practical allocation and oversight will come from agency guidance and grant terms.
That gap raises questions about how quickly funds translate into durable capacity versus short‑term purchases or contracts.
The financing approach also creates implementation tensions. Routing mandatory funding through the CCC guarantees availability outside the annual appropriations cycle, accelerating deployment, but that same mechanism reduces congressional appropriators’ routine levers of oversight and trade‑offs.
The bill pairs a near‑term surge in resources with a much smaller long‑term baseline, which can incentivize short‑term hiring and capital spending that proves unsustainable when the funding steps down; recipients and states will need to weigh whether to build permanent capacity or use funds for one‑time upgrades.
Operationally, the statute increases authorized support for laboratories and vaccine/countermeasure activities but leaves procurement timing, stockpiling standards, and intergovernmental roles underspecified. Those details will determine whether the money improves readiness measurably or mostly smooths episodic shortfalls during crises.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.